1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 68, 2017
  5. Article

Annual Review of Medicine

Volume 68, 2017

Cardiac Pacing and Defibrillation Devices: Cost and Effectiveness

Abstract

Implantable cardiac pacing and defibrillation devices are effective and commonly used therapies for patients with cardiac rhythm disorders. Because device implantation is not easily reversible, as well as the high healthcare costs inherent in device use, a clear understanding of the clinical benefits relative to costs is essential for both appropriate clinical use and rational policy making. Cardiac implantable electronic devices (CIEDs) have been among the best-investigated therapies in medicine; these devices have been the topic of numerous clinical and economic evaluations during the past 30 years. However, many important questions remain unclarified. We review the evidence supporting the clinical benefits of CIEDs, including effectiveness in extending survival as well as improving quality of life. We also summarize the economic studies that have investigated costs associated with these devices and their overall cost effectiveness, and we highlight important potential areas for future research.

Keyword(s): arrhythmia, cardiac implantable electronic device, cardiac resynchronization therapy, cost-benefit analysis, implantable cardioverter-defibrillator, pacemaker, quality of life, sudden death
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-043015-123540
2017-01-14
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/med/68/1/annurev-med-043015-123540.html?itemId=/content/journals/10.1146/annurev-med-043015-123540&mimeType=html&fmt=ahah

Literature Cited

  1. Greenspon AJ, Patel JD, Lau E. 1.  et al. 2012. Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures. J. Am. Coll. Cardiol. 60:1540–45 [Crossref] [Google Scholar]
  2. Young JB, Abraham WT, Smith AL. 2.  et al. 2003. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289:2685–94 [Google Scholar]
  3. 3. Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. 1997. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med. 337:1576–83 [Google Scholar]
  4. Abraham WT, Fisher WG, Smith AL. 4.  et al. 2002. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 346:1845–53 [Google Scholar]
  5. Bardy GH, Lee KL, Mark DB. 5.  et al. 2005. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352:225–37 [Google Scholar]
  6. Bristow MR, Saxon LA, Boehmer J. 6.  et al. 2004. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350:2140–50 [Google Scholar]
  7. Buxton AE, Lee KL, Fisher JD. 7.  et al. 1999. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 341:1882–90 [Google Scholar]
  8. Cleland JG, Daubert JC, Erdmann E. 8.  et al. 2005. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352:1539–49 [Google Scholar]
  9. Connolly SJ, Kerr CR, Gent M. 9.  et al. 2000. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N. Engl. J. Med. 342:1385–91 [Google Scholar]
  10. Hohnloser SH, Kuck KH, Dorian P. 10.  et al. 2004. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J. Med. 351:2481–88 [Google Scholar]
  11. Lamas GA, Lee KL, Sweeney MO. 11.  et al. 2002. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N. Engl. J. Med. 346:1854–62 [Google Scholar]
  12. Lamas GA, Orav EJ, Stambler BS. 12.  et al. 1998. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N. Engl. J. Med. 338:1097–104 [Google Scholar]
  13. Moss AJ, Hall WJ, Cannom DS. 13.  et al. 1996. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 335:1933–40 [Google Scholar]
  14. Moss AJ, Hall WJ, Cannom DS. 14.  et al. 2009. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361:1329–38 [Google Scholar]
  15. Moss AJ, Zareba W, Hall WJ. 15.  et al. 2002. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346:877–83 [Google Scholar]
  16. Reddy VY, Exner DV, Cantillon DJ. 16.  et al. 2015. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N. Engl. J. Med. 373:1125–35 [Google Scholar]
  17. Sanders GD, Hlatky MA, Owens DK. 17.  2005. Cost-effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med. 353:1471–80 [Google Scholar]
  18. Tang AS, Wells GA, Talajic M. 18.  et al. 2010. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363:2385–95 [Google Scholar]
  19. McClellan MB, Tunis SR. 19.  2005. Medicare coverage of ICDs. N. Engl. J. Med. 352:222–24 [Google Scholar]
  20. Larsen G, Hallstrom A, McAnulty J. 20.  et al. 2002. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 105:2049–57 [Google Scholar]
  21. Sanders GD, Hlatky MA, Every NR. 21.  et al. 2001. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann. Intern. Med. 135:870–83 [Google Scholar]
  22. O'Brien BJ, Connolly SJ, Goeree R. 22.  et al. 2001. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 103:1416–21 [Google Scholar]
  23. Mushlin AI, Hall WJ, Zwanziger J. 23.  et al. 1998. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 97:2129–35 [Google Scholar]
  24. Owens DK, Sanders GD, Harris RA. 24.  et al. 1997. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann. Intern. Med. 126:1–12 [Google Scholar]
  25. Kadish A, Goldberger J. 25.  2011. Selecting patients for ICD implantation: Are clinicians choosing appropriately?. JAMA 305:91–92 [Google Scholar]
  26. Hsu JC, Marcus GM, Al-Khatib SM. 26.  et al. 2014. Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. J. Am. Coll. Cardiol. 64:256–64 [Google Scholar]
  27. Hartman M, Martin AB, Lassman D. 27.  et al. 2015. National health spending in 2013: Growth slows, remains in step with the overall economy. Health Aff. 34:150–60 [Google Scholar]
  28. Mozaffarian D, Benjamin EJ, Go AS. 28.  et al. 2016. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133:e38–e360 [Google Scholar]
  29. Brignole M, Auricchio A, Baron-Esquivias G. 29.  et al. 2013. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on Cardiac Pacing and Resynchronization Therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur. Heart J. 34:2281–329 [Google Scholar]
  30. Tracy CM, Epstein AE, Darbar D. 30.  et al. 2012. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 126:1784–800 [Google Scholar]
  31. Epstein AE, DiMarco JP, Ellenbogen KA. 31.  et al. 2008. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation 117:e350–408 [Google Scholar]
  32. Castelnuovo E, Stein K, Pitt M. 32.  et al. 2005. Cost-effectiveness of dual-chamber pacing. The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation. Health Technol. Assess. 9:4773–106 [Google Scholar]
  33. Neumann PJ, Cohen JT, Weinstein MC. 33.  2014. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N. Engl. J. Med. 371:796–97 [Google Scholar]
  34. Connolly SJ, Gent M, Roberts RS. 34.  et al. 2000. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297–302 [Google Scholar]
  35. Siebels J, Kuck KH. 35.  1994. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am. Heart J. 127:1139–44 [Google Scholar]
  36. Linde C, Abraham WT, Gold MR. 36.  et al. 2008. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol. 52:1834–43 [Google Scholar]
  37. DeMaso DR, Lauretti A, Spieth L. 37.  et al. 2004. Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. Am. J. Cardiol. 93:582–87 [Google Scholar]
  38. Eckert M, Jones T. 38.  2002. How does an implantable cardioverter defibrillator (ICD) affect the lives of patients and their families?. Int. J. Nurs. Pract. 8:152–57 [Google Scholar]
  39. Godemann F, Butter C, Lampe F. 39.  et al. 2004. Determinants of the quality of life (QoL) in patients with an implantable cardioverter/defibrillator (ICD). Qual. Life Res. 13:411–16 [Google Scholar]
  40. Carroll DL, Hamilton GA. 40.  2005. Quality of life in implanted cardioverter defibrillator recipients: the impact of a device shock. Heart Lung 34:169–78 [Google Scholar]
  41. Sears SF, Lewis TS, Kuhl EA. 41.  et al. 2005. Predictors of quality of life in patients with implantable cardioverter defibrillators. Psychosomatics 46:451–57 [Google Scholar]
  42. Groeneveld PW, Matta MA, Suh JJ. 42.  et al. 2007. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era. Pacing Clin. Electrophysiol. 30:463–71 [Google Scholar]
  43. Hsu J, Uratsu C, Truman A. 43.  et al. 2002. Life after a ventricular arrhythmia. Am. Heart J. 144:404–12 [Google Scholar]
  44. Irvine J, Dorian P, Baker B. 44.  et al. 2002. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am. Heart J. 144:282–89 [Google Scholar]
  45. Schron EB, Exner DV, Yao Q. 45.  et al. 2002. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105:589–94 [Google Scholar]
  46. Sheldon R, O'Brien BJ, Blackhouse G. 46.  et al. 2001. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian Implantable Defibrillator Study. Circulation 104:1622–26 [Google Scholar]
  47. Weiss JP, Saynina O, McDonald KM. 47.  et al. 2002. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am. J. Med. 112:519–27 [Google Scholar]
  48. Mark DB, Nelson CL, Anstrom KJ. 48.  et al. 2006. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114:135–42 [Google Scholar]
  49. Woo CY, Strandberg EJ, Schmiegelow MD. 49.  et al. 2015. Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. Ann. Intern. Med. 163:417–26 [Google Scholar]
  50. Al-Khatib SM, Hellkamp A, Curtis J. 50.  et al. 2011. Non-evidence-based ICD implantations in the United States. JAMA 305:43–49 [Google Scholar]
  51. Farmer SA, Kirkpatrick JN, Heidenreich PA. 51.  et al. 2009. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm 6:325–31 [Google Scholar]
  52. Zweibel S, Clyne C, Crespo E. 52.  2011. ICD implantation and evidence-based patient selection. JAMA 305:1538–39 [Google Scholar]
  53. Burke JF, Hayward RA, Nelson JP. 53.  et al. 2014. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ. Cardiovasc. Qual. Outcomes 7:163–69 [Google Scholar]
  54. Goldberger JJ, Buxton AE, Cain M. 54.  et al. 2011. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation 123:2423–30 [Google Scholar]
  55. Pocock SJ, Ariti CA, McMurray JJ. 55.  et al. 2013. Predicting survival in heart failure: a risk score based on 39,372 patients from 30 studies. Eur. Heart J. 34:1404–13 [Google Scholar]
  56. Al-Khatib SM, Hellkamp AS, Fonarow GC. 56.  et al. 2014. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. JAMA 311:2209–15 [Google Scholar]
  57. Groeneveld PW, Sonnad SS, Lee AK. 57.  et al. 2006. Racial differences in attitudes toward innovative medical technology. J. Gen. Intern. Med. 21:559–63 [Google Scholar]
  58. Spertus JA, Bach R, Bethea C. 58.  et al. 2015. Improving the process of informed consent for percutaneous coronary intervention: patient outcomes from the Patient Risk Information Services Manager (ePRISM) study. Am. Heart J. 169:234–41 [Google Scholar]
  59. Reynolds MR, Cohen DJ, Kugelmass AD. 59.  et al. 2006. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. J. Am. Coll. Cardiol. 47:2493–97 [Google Scholar]
  60. Groeneveld PW, Matta MA, Suh JJ. 60.  et al. 2006. Costs and quality-of-life effects of implantable cardioverter-defibrillators. Am. J. Cardiol. 98:1409–15 [Google Scholar]
  61. Tomzik J, Koltermann KC, Zabel M. 61.  et al. 2015. Quality of life in patients with an implantable cardioverter defibrillator: a systematic review. Front. Cardiovasc. Med. 2:34 [Google Scholar]
  62. Mastenbroek MH, Pedersen SS, van der Tweel I. 62.  et al. 2016. Results of ENHANCED implantable cardioverter defibrillator programming to reduce therapies and improve quality of life (from the ENHANCED-ICD Study). Am. J. Cardiol. 117:596–604 [Google Scholar]
  63. Kini V, Soufi MK, Deo R. 63.  et al. 2014. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: Are indications still met?. J. Am. Coll. Cardiol. 63:2388–94 [Google Scholar]
  64. Lewis WR, Luebke DL, Johnson NJ. 64.  et al. 2006. Withdrawing implantable defibrillator shock therapy in terminally ill patients. Am. J. Med. 119:892–96 [Google Scholar]
  65. Reddy VY, Knops RE, Sperzel J. 65.  et al. 2014. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation 129:1466–71 [Google Scholar]
  66. Pauly MV. 66.  2004. What if technology never stops improving? Medicare's future under continuous cost increases. Spec. Law Dig. Health Care Law 308:9–26 [Google Scholar]
  67. Nava S, Morales JL, Marquez MF. 67.  et al. 2013. Reuse of pacemakers: comparison of short and long-term performance. Circulation 127:1177–83 [Google Scholar]
  68. Laslett LJ, Alagona P Jr., Clark BA 3rd. 68.  et al. 2012. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J. Am. Coll. Cardiol. 60:S1–49 [Google Scholar]
/content/journals/10.1146/annurev-med-043015-123540
Loading
Cardiac Pacing and Defibrillation Devices: Cost and Effectiveness
Annual Review of Medicine 68, 1 (2017); https://doi.org/10.1146/annurev-med-043015-123540
/content/journals/10.1146/annurev-med-043015-123540
/content/journals/10.1146/annurev-med-043015-123540
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error